Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug

British Journal of Cancer

Volumn 79, Issue 9-10, 1999, Pages 1378-1385

  Cheng, T L ^a,b   Wei, S L ^c   Chen, B M ^a   Chern, J W ^d   Wu, M F ^e   Liu, P W ^c   Roffler, S R ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Antibody directed enzyme prodrug therapy; Bystander effect; Immunoconjugates; Monoclonal antibody; Prodrugs; glucuronidase

Indexed keywords

ANTIBODY CONJUGATE; BETA GLUCURONIDASE; GLUCURONIDE; MONOCLONAL ANTIBODY; PRODRUG;

ANIMAL CELL; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ARTICLE; CANCER INHIBITION; CELL DEATH; ENZYME ACTIVATION; HEPATOMA CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0032973530     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690221     Document Type: Article

References (22)

1. Bagshawe KD, Springer CJ, Searle F, Antoniw P, Sharma SK, Melton RG and Sherwood RF (1988) A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer 58: 700-703
2. Baxter LT, Yuan F and Jain RK (1992) Pharmacokinetic analysis of the perivascular distribution of bifunctional antibodies and haptens: comparison with experimental data. Cancer Res 52: 5838-5844
3. Chari RVJ, Jackel KA, Bourret LA, Derr SM, Tadayoni BM, Mattocks KM, Shah SA, Liu C, Blättler WA and Goldmacher VS (1995) Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation. Cancer Res 55: 4079-4084
4. Chen BM, Chan LY, Wang SM, Wu MF, Chem JW and Roffler SR (1997) Cure of malignant ascites and generation of protective immunity by monoclonal antibody targeted activation of a glucuronide prodrug in rats. Int J Cancer 73: 392-402
5. Cheng TL, Chen BM, Chan LY, Wu PY, Chern JW and Roffler SR (1997) Poly(ethylene glycol) modification of β-glucuronidase-antibody conjugates for solid tumor therapy by targeted activation of glucuronide prodrugs. Cancer Immun Immunother 44: 305-315
6. Douillard JY, Lehur PA, Aillet G, Kremer M, Bianco-Arco A, Peltier P and Chatal JF (1986) Immunohistochemical antigenic expression and in vivo tumor uptake of monoclonal antibodies with specificity for tumors of the gastrointestinal tract. Cancer Res 46: 4221-4224
7. Ejigu Retta BM, Burke PJ, Photiou A, Melton R and Eno-Amooquaye E (1996) Antibody-directed enzyme prodrug therapy (ADEPT): evidence for a bystander effect in vitro. Int J Oncol 9: 567-570
8. Fujimori K, Covell DG, Fletcher JE and Weinstein JN (1990) A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 31: 1191-1198
9. Gerlowski LE and Jain RK (1986) Microvascular permeability of normal and neoplastic tissues. Microvascular Res 31: 288-305
10. Jain RK (1990) Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 50: 814-819
11. Less JR, Posner MC, Boucher Y, Borochovitz D, Wolmark N and Jain RK (1992) Interstitial hypertension in human breast and colorectal tumors. Cancer Res 52: 6371-6374
12. Roffler SR, Wang SM, Chern JW, Yeh MY and Tung E (1991) Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate. Biochem Pharmacol 42: 2062-2065
13. Roffler SR, Chan J and Yeh MY (1994) Potentiation of radioimmunotherapy by inhibition of topoisomerase I. Cancer Res 54: 1276-1285
14. 90Y-labeled monoclonal antibody B72.3 after intraperitoneal administration. J Natl Cancer Inst 83: 1629-1636
15. Sahin U, Hartmann F, Senter P, Pohl C, Engert A, Diehl V and Pfreundschuh M (1990) Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody. Cancer Res 50: 6944-6948
16. Senter PD, Saulnier MG, Schreiber GJ, Hirschberg DL, Brown JP, Hellström I and Hellström KE (1988) Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci USA 85: 4842-4846
17. Shockley TR, Lin K, Sung C, Nagy JA, Tompkins RG, Dedrick RL, Dvorak HF and Yarmush ML (1992) A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: effects of antibody immunological properties and tumor antigen expression levels. Cancer Res 52: 357-366
18. Smith DF, Walborg EF and Chang TP (1970) Establishment of a transplantable ascites variant of a rat hepatoma induced by 3′-methyl-4-dimethylaminoazobenzene. Cancer Res 30: 2306-2309
19. Sung C, Dedrick RL, Hall WA, Johnson PA and Youle RJ (1993) The spatial distribution of immunotoxins in solid tumors: assessment by quantitative autoradiography. Cancer Res 53: 2092-2099
20. Tomlinson E (1990) Biological dispersion and the design of site-specific protein therapeutic systems. In Targeting of Drugs 2, Optimization Strategies. Gregoriadis G, Allison AC, Poste G (eds). pp 1-19. Plenum Press: New York
21. Wallace PM, Macmaster JF, Smith VF, Kerr DE, Senter PD and Cosand WL (1994) Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine. Cancer Res 54: 2719-2723
22. Wang SM, Chern JW, Yeh MY, Ng JC, Tung E and Roffler SR (1992) Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy. Cancer Res 52: 4484-4491